Lenalidomide Teva 2,5 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 2,5 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 2,5 mg - lenalidomidhydrochlorid hydrat 3.025 mg - lenalidomide

Lenalidomide Teva 5 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 5 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 5 mg - lenalidomidhydrochlorid hydrat 6.05 mg - lenalidomide

Lenalidomide Teva 7,5 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 7,5 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 7,5 mg - lenalidomidhydrochlorid hydrat 9.075 mg - lenalidomide

Lenalidomide Teva 10 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 10 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 10 mg - lenalidomidhydrochlorid hydrat 12.1 mg - lenalidomide

Lenalidomide Teva 15 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 15 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 15 mg - lenalidomidhydrochlorid hydrat 18.15 mg - lenalidomide

Lenalidomide Teva 20 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 20 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 20 mg - lenalidomidhydrochlorid hydrat 24.2 mg - lenalidomide

Lenalidomide Teva 25 mg Hartkapsel Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lenalidomide teva 25 mg hartkapsel

teva - lenalidomidhydrochlorid hydrat - hartkapsel - 25 mg - lenalidomidhydrochlorid hydrat 30.25 mg - lenalidomide

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Europäische Union - Deutsch - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment

Lenalidomide Mylan Europäische Union - Deutsch - EMA (European Medicines Agency)

lenalidomide mylan

mylan ireland limited - lenalidomid - multiples myelom - immunsuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Lenalidomide Krka d.d. Europäische Union - Deutsch - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunsuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lympho